Carrying out a prospective study with long-term longitudinal follow-up appears essential to precisely assess the degree of improvement in the symptoms and quality of life of these patients, determine the most appropriate surgical techniques, and understand the pathophysiological mechanisms that may result in the implementation of specific treatments and relevant markers. From a surgical point of view, there is a real risk of fracture of implants whatever the type of intervention performed: study the biomechanical properties of implants with a view to characterizing their behavior to mechanical rupture but also their thermal resistance in an objective manner seems essential to limit the risk of fracture and help to inform the patient about the surgical technique proposed for explantation. From a biological point of view, the dosage of the metallic elements constituting ESSURE® implants and potentially toxic ones could make it possible to objectify the release of these metallic elements in the body. Analysis of pro-inflammatory cytokines, micro-RNAs (miRNA), quantitative analysis of inflammatory pathway messenger ribonucleic acid (mRNAs) (NanoString technology) and analysis of neuroinflammation by functional imaging should make it possible to explore potential pathophysiological mechanisms. This study responds to a significant request from patient associations. conditions: Implant Complication conditions: Contraceptive Device; Complications studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 444 type: ESTIMATED name: Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination name: blood sample name: urine collection name: Collection of a lock of hair name: questionnaire measure: Percentage of patients with improvement in symptoms Percentage of patients with improvement in symptoms measure: Percentage of patients with improvement in symptoms measure: Short Form 12 (SF-12) score measure: Fibromyalgia Impact Questionnaire (FIQ) score measure: Hospital Anxiety and Depression scale (HADS) score measure: Multidimensional Fatigue Inventory (MFI)-20 score measure: Visual analog scale (VAS) score measure: Questionnaire Douleur St-Antoine (QDSA) score measure: Female Sexual Function Index (FSFI) score measure: Higham questionnaires measure: visual analog scale (VAS) score measure: Duration of the procedure measure: Complications measure: characterization of the mechanical behavior of the implant measure: determination of the associated mechanical stress levels determination of the associated mechanical stress levels measure: quantification of the factors influencing these levels of mechanical stress measure: thermal resistance measure: risk of degradation measure: Concentrations of titanium constituting the Essure® implant measure: Concentrations of nickel constituting the Essure® implant measure: Concentrations of chromium constituting the Essure® implant measure: Concentrations of tin constituting the Essure® implant measure: Concentrations of platinum constituting the Essure® implant measure: Concentrations of iridium constituting the Essure® implant measure: Concentrations of molybdenum constituting the Essure® implant measure: Concentrations of manganese constituting the Essure® implant measure: Concentrations of tungsten constituting the Essure® implant measure: Concentrations of silver constituting the Essure® implant measure: Concentrations of iron constituting the Essure® implant measure: concentration of pro-inflammatory cytokines measure: expression profile of miRNAs measure: activated T lymphocyte profile measure: analysis of inflammatory pathway mRNAs measure: Percentage of detection of Human Leukocyte Antigen measure: Functional brain functions sex: FEMALE minimumAge: 35 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Angers city: Angers zip: 49933 country: France name: Guillaume Legendre, PU,PH role: CONTACT phone: 0241354635 phoneExt: +33 email: guillaume.legendre@chu-angers.fr name: Guillaume Legendre, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 47.46667 lon: -0.55 facility: Hôpital Femme Mère Enfant (Hospices Civils de Lyon) city: Bron zip: 69677 country: France name: Gautier Chene, PU,PH role: CONTACT phone: 0472355870 phoneExt: +33 email: gautier.chene@chu-lyon.fr name: Gautier Chene, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 45.73333 lon: 4.91667 facility: Hôpital Bicêtre city: Le Kremlin-Bicêtre zip: 94275 country: France name: Perrine CAPMAS, PU,PH role: CONTACT phone: 0145217714 phoneExt: +33 email: perrine.capmas@aphp.fr name: Perrine CAPMAS, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 48.81471 lon: 2.36073 facility: Hôpital Jeanne de Flandres city: Lille zip: 59037 country: France name: Victoire Delporte, PU,PH role: CONTACT phone: 0320446641 phoneExt: +33 email: victoire.delporte@chu-lille.fr name: Victoire Delporte, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 50.63297 lon: 3.05858 facility: Hôpital de La Conception city: Marseille zip: 13005 country: France name: Aubert Agostini, PU,PH role: CONTACT phone: 0491383702 phoneExt: +33 email: Aubert.AGOSTINI@ap-hm.fr name: Aubert Agostini, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 43.29551 lon: 5.38958 facility: Institut Mère Enfant Alix de Champagne, CHU Reims city: Reims zip: 51092 country: France name: Olivier Graesslin, PU,PH role: CONTACT phone: 0326783517 phoneExt: +33 email: ograesslin@chu-reims.fr name: Olivier Graesslin, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 49.25 lon: 4.03333 facility: CHU de Rouen city: Rouen zip: 76000 country: France name: Patrice Crochet, PU,PH role: CONTACT phone: 0232881054 phoneExt: +33 email: patrice.crochet@chu-rouen.fr name: Patrice Crochet, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 49.44313 lon: 1.09932 facility: Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg city: Strasbourg zip: 67200 country: France name: Thomas Boisrame, PU,PH role: CONTACT phone: 0388127458 phoneExt: +33 email: thomas.boisrame@chru-strasbourg.fr name: Thomas Boisrame, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 48.58392 lon: 7.74553 facility: Hôpital Paule de Viguier, CHU de Toulouse city: Toulouse zip: 31059 country: France name: Yann Tanguy Le Gac, PU,PH role: CONTACT phone: 0567771105 phoneExt: +33 email: tanguylegac.y@chu-toulouse.fr name: Yann Tanguy Le Gac, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 43.60426 lon: 1.44367 facility: Hôpital André Mignot, Centre Hospitalier de Versailles city: Versailles zip: 78157 country: France name: Pierre Panel, PU,PH role: CONTACT phone: 0139638936 phoneExt: +33 email: ppanel@ch-versailles.fr name: Pierre Panel, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 48.8 lon: 2.13333 hasResults: False